Hoe le, MD
Family Medicine · Santee, CANPI 1811945611
Payments from drug & device makers
Across 324 payments — averaging $13.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$407
- GSK$369
- Pfizer$333
- AstraZeneca$287
- Kowa Pharmaceuticals America, Inc.$203
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,30199%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 174 | $1,504 |
| Lilly USA, LLC | 21 | $407 |
| GSK | 16 | $369 |
| Pfizer | 17 | $333 |
| AstraZeneca | 16 | $287 |
| Kowa Pharmaceuticals America, Inc. | 13 | $203 |
| Novo Nordisk | 11 | $185 |
| Sunovion Pharmaceuticals Inc. | 11 | $162 |
| Abbott | 5 | $134 |
| Genentech USA, Inc. | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Novartis | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $51 |
| Seqirus USA Inc | 2 | $49 |
| Astellas Pharma US Inc | 2 | $45 |
| Bayer | 2 | $39 |
| Boehringer Ingelheim | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Amgen(2 entities) | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $23 |
| Edwards Lifesciences | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Merck | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $12 |
How this compares
$4,358 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 119 | $134,981 |
| EliquisApixaban | 61 | $69,470 |
| JanuviaSitagliptin Phosphate | 64 | $47,552 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $42,877 |
| XareltoRivaroxaban | 25 | $30,438 |
| AptiomEslicarbazepine Acetate | 12 | $28,980 |
| FarxigaDapagliflozin Propanediol | 21 | $26,378 |
| LinzessLinaclotide | 18 | $14,991 |
| OzempicSemaglutide | 16 | $14,706 |
| MyrbetriqMirabegron | 14 | $12,689 |
| LivaloPitavastatin Calcium | 16 | $11,965 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $11,734 |
| Atorvastatin Calcium | 651 | $5,067 |
| Entecavir | 15 | $4,922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 167 | $4,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $39 | $134,981119 claims |
| PfizerEliquis | $333 | $69,47061 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $369 | $54,61169 claims |
| MerckJanuvia | $14 | $47,55264 claims |
| Johnson & JohnsonXarelto | $17 | $30,43825 claims |
| AstraZenecaFarxiga, Nexium | $287 | $29,73434 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $162 | $28,98012 claims |
| AbbVieLinzess | $1,504 | $14,99118 claims |
| Novo NordiskOzempic | $185 | $14,70616 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $12,68914 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $203 | $11,96516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Santee
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.